(Q50894693)

24 March 2018

title

What's fueling the biotech engine? (English)

1 reference

24 March 2018

author name string

Saurabh Aggarwal

series ordinal

1

1 reference

24 March 2018

publication date

1 October 2007

1 reference

24 March 2018

published in

Nature Biotechnology

1 reference

24 March 2018

volume

25

1 reference

24 March 2018

issue

10

1 reference

24 March 2018

page(s)

1097-1104

1 reference

24 March 2018

cites work

As biotech turns 20...

1 reference

https://api.crossref.org/works/10.1038%2FNBT1007-1097

7 January 2021

Biopharmaceutical benchmarks 2006.

1 reference

https://api.crossref.org/works/10.1038%2FNBT1007-1097

7 January 2021

Correction of Anemia — Payoffs and Problems

1 reference

https://api.crossref.org/works/10.1038%2FNBT1007-1097

7 January 2021

Weighing the hazards of erythropoiesis stimulation in patients with cancer

1 reference

https://api.crossref.org/works/10.1038%2FNBT1007-1097

7 January 2021

Development trends for monoclonal antibody cancer therapeutics.

1 reference

https://api.crossref.org/works/10.1038%2FNBT1007-1097

7 January 2021

Monoclonal antibodies market

1 reference

https://api.crossref.org/works/10.1038%2FNBT1007-1097

7 January 2021

Rheumatoid arthritis market

1 reference

https://api.crossref.org/works/10.1038%2FNBT1007-1097

7 January 2021

https://api.crossref.org/works/10.1038%2FNBT1007-1097

1 reference

7 January 2021

Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study

1 reference

https://api.crossref.org/works/10.1038%2FNBT1007-1097

7 January 2021

The price of sight--ranibizumab, bevacizumab, and the treatment of macular degeneration

1 reference

https://api.crossref.org/works/10.1038%2FNBT1007-1097

7 January 2021

https://api.crossref.org/works/10.1038%2FNBT1007-1097

1 reference

7 January 2021

Diabetes Treatment — Bridging the Divide

1 reference

https://api.crossref.org/works/10.1038%2FNBT1007-1097

7 January 2021

Biogen, Serono squabble over MS market

1 reference

https://api.crossref.org/works/10.1038%2FNBT1007-1097

7 January 2021

Off-label reports of new biologics: exciting new therapy or dubious research? Examples from recombinant activated factor VII.

1 reference

https://api.crossref.org/works/10.1038%2FNBT1007-1097

7 January 2021

Lyme disease: Uphill Struggle

1 reference

https://api.crossref.org/works/10.1038%2FNBT1007-1097

7 January 2021

The future of rotavirus vaccines: a major setback leads to new opportunities

1 reference

https://api.crossref.org/works/10.1038%2FNBT1007-1097

7 January 2021

The price tag on progress--chemotherapy for colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNBT1007-1097

7 January 2021

Can we RESOLVE the treatment of sepsis?

1 reference

https://api.crossref.org/works/10.1038%2FNBT1007-1097

7 January 2021

Images in clinical medicine. Calcinosis associated with renal failure

1 reference

https://api.crossref.org/works/10.1038%2FNBT1007-1097

7 January 2021

Regulation of follow-on biologics

1 reference

https://api.crossref.org/works/10.1038%2FNBT1007-1097

7 January 2021

The FDA's assessment of follow-on protein products: a historical perspective

1 reference

https://api.crossref.org/works/10.1038%2FNBT1007-1097

7 January 2021

Identifiers

DOI

10.1038/NBT1007-1097

1 reference

24 March 2018

1 reference

24 March 2018